🔎 Trials Near Me

Home › Neuroblastoma › District of Columbia

Pag-aaral pangklinika para sa Neuroblastoma sa District of Columbia

6 pag-aaral para sa Neuroblastoma ang naghahanap ng mga kalahok sa mga site sa District of Columbia.

Mga Lungsod sa District of Columbia

Opisyal na teksto ng pag-aaral (English)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Children's National Medical Center, Washington D.C.
Nagre-recruitPhase 3
Hanggang edad 30 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06172296

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Children's National Medical Center, Washington D.C.
Nagre-recruitPhase 3
365 Days – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's National Medical Center, Washington D.C.
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

  • Children's National Hospital, Washington D.C.
  • Childrens National Hospital, Washington D.C.
Nagre-recruitPhase 1
Edad 1 hanggang 23 · Lahat ng kasarian · Na-update Ago 13, 2026 · NCT07172958

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  • Children's National Medical Center, Washington D.C.
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update May 19, 2026 · NCT04901702

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

  • Children's National Medical Center, Washington D.C.
Nagre-recruitPhase 2
18 Months – 40 Years · Lahat ng kasarian · Na-update Ago 12, 2025 · NCT05135975

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.